Cobra Biologics Announces Development Projects - - BioPharm International

ADVERTISEMENT

Cobra Biologics Announces Development Projects


Cobra Biologics and Novolytics announced that the companies have developed two Staphylococcus aureus-based phage products for Phase I clinical trials with a 100-fold increase in upstream process yields. An existing process was transferred to Cobra’s phage team, which further developed the process in order to increase yields for the two S. aureus-based phage products. The process provides a path to producing suitable GMP material for human clinical trials, according to a Cobra Biologics press release.

In May, Cobra and Recopharma, a biotechnology company developing ophthalmic products, announced that Cobra Biologics will use its maxXpress platform service to deliver a program of vector construction using the UCOE technology, transfectant pool generation, and supply, purification, and protein characterization for a human Fc-fusion protein.

Cobra also announced that it will manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, using its platform process to deliver a program of host strain generation, GMP cell banking, plasmid DNA production, and clinical trials supply.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here